171 related articles for article (PubMed ID: 21897267)
1. Association of keap1 and nrf2 genetic mutations and polymorphisms with endometrioid endometrial adenocarcinoma survival.
Wong TF; Yoshinaga K; Monma Y; Ito K; Niikura H; Nagase S; Yamamoto M; Yaegashi N
Int J Gynecol Cancer; 2011 Nov; 21(8):1428-35. PubMed ID: 21897267
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of hormone-dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms.
Almeida M; Soares M; Ramalhinho AC; Moutinho JF; Breitenfeld L
Mol Biol Rep; 2019 Jun; 46(3):3213-3224. PubMed ID: 30941643
[TBL] [Abstract][Full Text] [Related]
5. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.
Konstantinopoulos PA; Spentzos D; Fountzilas E; Francoeur N; Sanisetty S; Grammatikos AP; Hecht JL; Cannistra SA
Cancer Res; 2011 Aug; 71(15):5081-9. PubMed ID: 21676886
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
7. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
9. Association of KEAP1 and NFE2L2 polymorphisms with temporal lobe epilepsy and drug resistant epilepsy.
Liu Z; Yin X; Liu L; Tao H; Zhou H; Ma G; Cui L; Li Y; Zhang S; Xu Z; Yao L; Cai Z; Zhao B; Li K
Gene; 2015 Oct; 571(2):231-6. PubMed ID: 26149655
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of the Nrf2 pathway in colorectal cancer: Nrf2 expression is closely correlated to Keap1 in the tumor and Bach1 in the normal tissue.
Chang LC; Fan CW; Tseng WK; Chen JR; Chein HP; Hwang CC; Hua CC
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):511-7. PubMed ID: 23455180
[TBL] [Abstract][Full Text] [Related]
11. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.
Cho HY; Kim K; Kim YB; Kim H; No JH
Int J Gynecol Cancer; 2017 Mar; 27(3):412-419. PubMed ID: 28129239
[TBL] [Abstract][Full Text] [Related]
12. The NRF2 transcriptional target NQO1 has low mRNA levels in TP53-mutated endometrial carcinomas.
Beinse G; Just PA; Rance B; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Pasmant E; Batteux F; Borghese B; Alexandre J; Leroy K
PLoS One; 2019; 14(3):e0214416. PubMed ID: 30908539
[TBL] [Abstract][Full Text] [Related]
13. Dysregulation of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer.
Ahtikoski AM; Kangas J; Salonen R; Puistola U; Karihtala P
Anticancer Res; 2019 Feb; 39(2):585-590. PubMed ID: 30711933
[TBL] [Abstract][Full Text] [Related]
15. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
[TBL] [Abstract][Full Text] [Related]
16. KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma.
Li QK; Singh A; Biswal S; Askin F; Gabrielson E
J Hum Genet; 2011 Mar; 56(3):230-4. PubMed ID: 21248763
[TBL] [Abstract][Full Text] [Related]
17. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
[TBL] [Abstract][Full Text] [Related]
18. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel Nrf2/Keap1 pathway mutations in pediatric acute lymphoblastic leukemia.
Akın-Balı DF; Aktas SH; Unal MA; Kankılıc T
Pediatr Hematol Oncol; 2020 Feb; 37(1):58-75. PubMed ID: 31661353
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.
Fabrizio FP; Sparaneo A; Trombetta D; Muscarella LA
Oxid Med Cell Longev; 2018; 2018():2492063. PubMed ID: 29643973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
